Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase

European Journal of Haematology

Volumn 80, Issue 4, 2008, Pages 331-336

  Hummel, Margit ^a   Reiter, Sebastian ^a   Adam, Katja ^a   Hehlmann, Ruediger ^a   Buchheidt, Dieter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hematologic malignancies; Hyperuricemia; Rasburicase; Renal failure; Tumor lysis syndrome

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CREATININE; PROTEIN TYROSINE KINASE INHIBITOR; RASBURICASE; STEROID; URIC ACID;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 40449091758     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01013.x     Document Type: Article

References (22)

1. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, van den BH. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003 98 : 1048 54.
2. Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981 41 : 2273 9.
3. Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 1992 8 : 315 8.
4. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001 15 : 1505 9.
5. Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986 109 : 292 8.
6. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970 283 : 354 7.
7. Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987 33 : 2314 6.
8. LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Moritz ML. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007 22 : 132 5.
9. Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972 17 : 890 5.
10. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001 19 : 697 704.
11. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001 97 : 2998 3003.
12. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004 127 : 3 11.
13. Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972 21 : 771 8.
14. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005 19 : 34 8.
15. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003 21 : 4402 6.
16. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003 17 : 2542 4.
17. Lee AC, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003 37 : 1614 7.
18. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005 29 : 463 5.
19. Arnold TM, Reuter JP, Delman BS, Shanholtz CB. Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004 38 : 1428 31.
20. Hummel M, Buchheidt D, Reiter S, Bergmann J, Adam K, Hehlmann R. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005 75 : 518 21.
21. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006 26 : 806 12.
22. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006 37 : 997 1001.